HC Wainwright Reiterates Buy Rating on Septerna, Inc. (SEPN)
HC Wainwright reiterated its buy rating on Septerna, Inc., setting a price target of $40, a 19.44% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on Septerna, Inc. (SEPN) with a price target of $40 on July 1, 2026.
- HC Wainwright's $40 price target implies 19.44% upside from Septerna, Inc.'s ($SEPN) current $33.49 share price.
- Septerna, Inc. trades near $33.49 on NasdaqGM with a market cap of $1.51 billion, focusing on GPCR oral small molecule products.
- Insiders and institutional investors like Goldman Sachs have made recent trades, with analysts maintaining strong buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On July 1, 2026, HC Wainwright reiterated its buy rating on Septerna, Inc. (NasdaqGM: SEPN) with a price target of $40. The stock traded near $33.49 on Wednesday, reflecting confidence in its biotechnology developments.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Septerna, Inc.
Goldman Sachs Group Inc added 191,298 shares to its holdings, bringing its total to 2,906,427 shares valued at about $69.84 million, marking a 7.0% increase. Meanwhile, Driehaus Capital Management LLC reduced its position by 413,898 shares, leaving it with 4,395,572 shares worth approximately $105.63 million, an 8.6% decrease.
Septerna, Inc. Stock Down 13.9%
Shares of Septerna, Inc. (NasdaqGM: SEPN) traded near $33.49 on Wednesday. The company has a market cap of about $1.51 billion. Although it is not currently profitable, it has a forward P/E ratio of -12.59. The stock's 52-week range is between $10.30 and $37.99, with moving averages of $29.11 over 50 days and $25.41 over 200 days. Septerna maintains a strong liquidity position with a current ratio of 4.71 and a quick ratio of 4.63.
$SEPN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
For the recent period, Septerna reported revenue of $72.26 million, showing a growth of 120.11%. However, the company recorded a net margin of -49.88% and a return on equity of -9.26%, indicating ongoing challenges in turning a profit. The next earnings report is expected on May 11, 2026.
Insider Buying and Selling at Septerna, Inc.
On June 29, 2026, Chief People Officer Samira Shaikhly executed multiple transactions, including a planned sale of 2,178 shares at an average price of $35.18. Additionally, Shaikhly acquired 2,178 shares at $6.81, not under a planned sale. On June 26, 2026, insiders Bernard Coulie and Alan Ezekowitz each bought 15,000 shares, enhancing their positions in the company.
Analysts Set New Price Targets
On July 1, 2026, multiple analysts echoed confidence in Septerna. Guggenheim maintained a buy rating with a $45 target, while Truist Securities also reaffirmed a buy with a $43 target. HC Wainwright & Co. reiterated its buy rating with a $40 target. Overall, the consensus remains strong buy, with an average target price of $44.89 from nine analysts.
About Septerna, Inc.
Septerna, Inc. is a biotechnology firm based in South San Francisco, California. It focuses on developing oral small molecule treatments targeting G protein-coupled receptors (GPCRs) for various diseases, including endocrinology and immunology disorders. Led by CEO Dr. Jeffrey T. Finer, the company collaborates with Novo Nordisk on metabolic-related therapies.
Bottom Line
HC Wainwright's reiterated buy rating on Septerna, Inc. with a $40 target reflects ongoing analyst confidence in the company's potential. Investors often track such ratings to gauge market sentiment, but it's important to remember that these are backward-looking assessments. As always, individual investment decisions should be based on a comprehensive analysis of current market conditions and personal financial circumstances.
Get Septerna, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SEPN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.